Jefferies analyst Akash Tewari upgraded Regeneron Pharmaceuticals to Buy from Hold with a price target of $925, up from $675.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron May Win Big with New Drug
- Raymond James ups Regeneron to Market Perform as few downside catalysts remain
- Regeneron upgraded to Market Perform from Underperform at Raymond James
- Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints
- Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial